WBR0430: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
|MainCategory=Pathology
|MainCategory=Pathology
|SubCategory=Hematology
|SubCategory=Hematology
|MainCategory=Pathology
|MainCategory=Pathology
|MainCategory=Pathology
|MainCategory=Pathology
|MainCategory=Pathology
Line 26: Line 27:
Stage II: Between stage I and III
Stage II: Between stage I and III
Stage III: Serum β2 microglobulin ≥ 5.5 mg/L
Stage III: Serum β2 microglobulin ≥ 5.5 mg/L
|EducationalObjectives= [[Multiple myeloma]] staging does not utilize the TNM system.  Instead, the [[International Staging System]] (ISS) for multiple myeloma is dependent on levels of serum β2 microglobulin and albumin.
|References= Mihou D, Katodritou E, Zervas K. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.  Hematology.  2007;12(6):527-31.
|AnswerA=BUN/Creatinine ratio
|AnswerA=BUN/Creatinine ratio
|AnswerAExp=A [[BUN/Creatinine ratio]], not useful for staging multiple myeloma, aids in distinguishing between types of renal injury (pre-renal, instrinsic, or post-renal).
|AnswerAExp=A [[BUN/Creatinine ratio]], not useful for staging multiple myeloma, aids in distinguishing between types of renal injury (pre-renal, instrinsic, or post-renal).
|AnswerB=β2 microglobulin and albumin levels
|AnswerB=β2 microglobulin and albumin levels
|AnswerBExp= Serum β2 microglobulin and albumin levels are used by the ISS for staging multiple myeloma.
|AnswerBExp=Serum β2 microglobulin and albumin levels are used by the ISS for staging multiple myeloma.
|AnswerC=CA-125 level
|AnswerC=CA-125 level
|AnswerCExp=CA-125 levels are frequently checked in the follow-up of patients with ovarian cancer, but should not be used for diagnostic purposes.
|AnswerCExp=CA-125 levels are frequently checked in the follow-up of patients with ovarian cancer, but should not be used for diagnostic purposes.
|AnswerD=p53 and Retinoblastoma gene (Rb) activities
|AnswerD=Serum calcium
|AnswerDExp=The tumor suppressor genes, p53 and Rb, are inactivated in many cancers, but are not useful for staging multiple myeloma.
|AnswerDExp=Multiple myeloma causes lytic lesions in the bone, thereby releasing stored calcium.  However, serum calcium is not a prognostic marker for multiple myeloma patients.
|AnswerE=Hemoglobin S levels
|AnswerE=Spread to lymph nodes
|AnswerEExp=Hemoglobin S levels, detected by hemoglobin electrophoresis, is used in the diagnosis of sickle cell disease.
|AnswerEExp=Most solid tumors utilize the TNM staging system in which the following three stages exist. Stage 1: Tumor is confined to the primary site. Stage 2: The tumor has spread to the lymph nodes. Stage 3: The tumor has distant metastases.  <br>
In contrast, the International Staging System is used for multiple myeloma. Lymph node involvement is not one of the criteria in this framework.
|EducationalObjectives=[[Multiple myeloma]] staging does not utilize the TNM system.  Instead, the [[International Staging System]] (ISS) for multiple myeloma is dependent on levels of serum β2 microglobulin and albumin.
|References=Mihou D, Katodritou E, Zervas K. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.  Hematology.  2007;12(6):527-31.
|RightAnswer=B
|RightAnswer=B
|WBRKeyword= beta-2-microglobulin, albumin, multiplemyeloma, anemia, hypercalcemia, bone, renal, staging, ISS, rouleaux formation
|WBRKeyword=Beta-2-microglobulin, Albumin, Multiple myeloma, Anemia, Hypercalcemia, Bone, Renal, Staging, ISS, Rouleaux formation, Rouleaux
|Approved=Yes
|Approved=Yes
}}
}}

Revision as of 19:52, 11 January 2015

 
Author [[PageAuthor::Rim Halaby, M.D. [1], Alison Leibowitz [2] (Reviewed by Alison Leibowitz)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Pathology
Sub Category SubCategory::Hematology
Prompt [[Prompt::A 78-year-old male presents to the physician’s office with complaints of back pain, which is not relieved by medications, and fatigue of several weeks duration. Evaluation reveals anemia, elevated levels of serum calcium, and renal insufficiency. A peripheral smear of the patient’s blood shows characteristic “rouleaux formation”, characteristic of multiple myeloma. Which of the following markers is most frequently used for the staging of multiple myeloma?]]
Answer A AnswerA::BUN/Creatinine ratio
Answer A Explanation [[AnswerAExp::A BUN/Creatinine ratio, not useful for staging multiple myeloma, aids in distinguishing between types of renal injury (pre-renal, instrinsic, or post-renal).]]
Answer B AnswerB::β2 microglobulin and albumin levels
Answer B Explanation AnswerBExp::Serum β2 microglobulin and albumin levels are used by the ISS for staging multiple myeloma.
Answer C AnswerC::CA-125 level
Answer C Explanation AnswerCExp::CA-125 levels are frequently checked in the follow-up of patients with ovarian cancer, but should not be used for diagnostic purposes.
Answer D AnswerD::Serum calcium
Answer D Explanation AnswerDExp::Multiple myeloma causes lytic lesions in the bone, thereby releasing stored calcium. However, serum calcium is not a prognostic marker for multiple myeloma patients.
Answer E AnswerE::Spread to lymph nodes
Answer E Explanation [[AnswerEExp::Most solid tumors utilize the TNM staging system in which the following three stages exist. Stage 1: Tumor is confined to the primary site. Stage 2: The tumor has spread to the lymph nodes. Stage 3: The tumor has distant metastases.

In contrast, the International Staging System is used for multiple myeloma. Lymph node involvement is not one of the criteria in this framework.]]

Right Answer RightAnswer::B
Explanation [[Explanation::Multiple myeloma, a common hematologic cancer characterized by monoclonal gammopathy, frequently manifests with hypercalcemia, renal insufficiency, anemia, and lytic bone lesions (mnemonic: CRAB – Calcium, Renal, Anemia, Bone). Rouleaux formation on peripheral smear is also characteristic of multiple myeloma.

Multiple myeloma staging does not utilize the TNM system. Instead, the International Staging System (ISS) for multiple myeloma depends on levels of serum β2 microglobulin and albumin. Stage I: Serum β2 microglobulin < 3.5 mg/L and serum albumin ≥ 3.5 g/dL Stage II: Between stage I and III Stage III: Serum β2 microglobulin ≥ 5.5 mg/L
Educational Objective: Multiple myeloma staging does not utilize the TNM system. Instead, the International Staging System (ISS) for multiple myeloma is dependent on levels of serum β2 microglobulin and albumin.
References: Mihou D, Katodritou E, Zervas K. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model. Hematology. 2007;12(6):527-31.]]

Approved Approved::Yes
Keyword WBRKeyword::Beta-2-microglobulin, WBRKeyword::Albumin, WBRKeyword::Multiple myeloma, WBRKeyword::Anemia, WBRKeyword::Hypercalcemia, WBRKeyword::Bone, WBRKeyword::Renal, WBRKeyword::Staging, WBRKeyword::ISS, WBRKeyword::Rouleaux formation, WBRKeyword::Rouleaux
Linked Question Linked::
Order in Linked Questions LinkedOrder::